v3.26.1
Condensed Consolidated Statements of Changes in Stockholders’ Deficit (Unaudited) - DIAMIR BIOSCIENCES CORP. - USD ($)
Common Stock
Additional Paid in Capital
Accumulated Deficit
Total
Balance at May. 31, 2023 $ 4,441 $ 4,440,256 $ (4,464,931) $ (20,234)
Balance (in Shares) at May. 31, 2023 4,440,891      
Stock compensation expense   194,846   194,846
Discount on note payable to founder   35,063   35,063
Net loss (614,405) (614,405)
Balance at May. 31, 2024 $ 4,441 4,670,165 (5,079,336) (404,730)
Balance (in Shares) at May. 31, 2024 4,440,891      
Stock compensation expense   24,312   24,312
Discount on note payable to founder   24,970   24,970
Net loss     (493,710) (493,710)
Balance at Feb. 28, 2025 $ 4,441 4,719,447 (5,573,046) (849,158)
Balance (in Shares) at Feb. 28, 2025 4,440,891      
Balance at May. 31, 2024 $ 4,441 4,670,165 (5,079,336) (404,730)
Balance (in Shares) at May. 31, 2024 4,440,891      
Stock compensation expense   24,312   24,312
Discount on note payable to founder   34,692   34,692
Net loss (743,235) (743,235)
Balance at May. 31, 2025 $ 4,441 4,729,169 (5,822,571) (1,088,961)
Balance (in Shares) at May. 31, 2025 4,440,891      
Discount on note payable to founder   12,694   12,694
Net loss     (349,842) (349,842)
Balance at Feb. 28, 2026 $ 4,441 $ 4,741,863 $ (6,172,413) $ (1,426,109)
Balance (in Shares) at Feb. 28, 2026 4,440,891